PhRMA Submits Comments to White House on Artificial Intelligence
We live in an era where technology is increasingly shaping our daily routines. In the biopharmaceutical sector, harnessing artificial intelligence (AI) can boost efficiency, facilitate the discovery of new cures and treatments, and strengthen clinical trials.
The American biopharmaceutical industry is supported by strong intellectual property protections and a flexible regulatory framework, both of which encourage life-saving innovations in the United States.
Recently, the trade association Pharmaceutical Research Manufacturers of America (PhRMA) submitted comments in response to the White House Office of Science and Technology Policy’s request for information on creating a national AI action plan.
Source: https://www.thepharmaletter.com/phrma-submits-comments-to-white-house-on-artificial-intelligence